Connect your AI

Pulmonx Corporation LUNG Debt Instrument, Paid-In-Kind Interest

Other financials

Income statement

Revenue$20.6M-8.7%

Gross profit$16.0M-1.8%

Operating income-$13.0M+11.0%

Net income-$13.7M+5.5%

EPS (diluted)-$0.33+8.3%

Balance sheet

Cash & equivalents$61.0M-2.4%

Total debt$56.3M-1.2%

Total equity$45.8M-41.1%

Total assets$120.0M-20.4%

Cash flow

Operating cash flow-$10.1M+23.6%

CapEx$9.0K-97.0%

Free cash flow-$10.1M+25.3%

Valuation

Market cap$54.91M-43.7%

Enterprise value$50.17M-39.2%

P/S0.6×-0.5×

Profitability

Gross margin75.5%+2.0pp

Operating margin-58.8%-5.8pp

Net margin-60.1%-4.4pp

FCF margin-33.2%-4.4pp

Returns & leverage

Return on equity-86.2%+62.6pp

Debt / equity1.2×+0.5×

Current ratio4.9×-0.1×

Where this comes from

Reported directly by Pulmonx Corporation in its filing.

Tagged under the XBRL concept lung:DebtInstrumentPaidInKindInterest.

The official record: Pulmonx Corporation’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about Pulmonx Corporation's debt instrument, paid-in-kind interest.

Connect your AI assistant and see it in context, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Pulmonx Corporation's debt instrument, paid-in-kind interest?: Pulmonx Corporation (LUNG) reported debt instrument, paid-in-kind interest of $2.44M in Q1 2026.